Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. Design studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results

COVID-19 severe or critically meta-analysis

Cao RCTruxolitinibvitamin CCOVID-19 severe or criticallysome concern
21/21 suggested
  • suggested 4.5-fold increase in radiologic improvement (14-day) with a moderate degree of certainty due to some concern in risk of bias
DEVENT unpublished
 
NCT04377620
RCTruxolitinibplaceboCOVID-19 severe or criticallyNA
-/- suggested
  • suggested 53 % decrease in deaths

PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).